NMN adds raw material to the NAD+ pathway as a building block
BPC-157 upregulates survival genes (Akt1, KRAS, Src, Foxo1), reduces inflammatory mediators (IL-6, TNF-, NOS2, NFB), scavenges reactive oxygen species through its four carboxylic groups, activates vascular bypass pathways, and maintains blood flow despite vessel occlusion
Current Research Limitations Most clinical studies on GHK-Cu involve: Topical formulations In vitro research Animal models Systemic (non-injectable) delivery There is insufficient evidence in peer-reviewed literature to support: standardized injection techniques validated injectable dosing regimens long-term safety or efficacy data for injectable use As a result, clinicians should approach injectable discussions with caution and rely on evidence-based peptide education rather than anecdotal protocols
The batch-specific Certificate of Analysis is published on our COA page, where you can match your vial's batch number to its results